PD-L1 and tumor-infiltrating CD8+ lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas

Pediatric pituitary adenomas are more aggressive, more likely to be hormone producing and are more difficult to cure than adult pituitary adenomas: case series and systematic literature review

(2022) Alexander P. Kelly et al.   CHILDS NERVOUS SYSTEM

High-risk pituitary adenomas and strategies for predicting response to treatment

(2022) George Kontogeorgos et al.   Hormones-International Journal of Endocrinology and Metabolism

Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report

(2022) Sanjit Shah et al.   NEUROSURGERY

Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study

(2022) Mirela Diana Ilie et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors

(2021) Shuhang Wang et al.   BMC Medicine

Research advances on the immune research and prospect of immunotherapy in pituitary adenomas

(2021) Ding Nie et al.   World Journal of Surgical Oncology

Should pituitary carcinoma be treated using a NET‐like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy

(2021) Bernard Goichot et al.   CLINICAL ENDOCRINOLOGY

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness

(2020) Zihao Wang et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature

(2020) Camille Duhamel et al.   Journal of Personalized Medicine

The Epidemiology of Pituitary Adenomas

(2020) Adrian F. Daly et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas

(2020) Wenjianlong Zhou et al.   JOURNAL OF NEURO-ONCOLOGY

Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma

(2020) Guodong Zhao et al.   World Neurosurgery

Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study

(2020) Nazanin Majd et al.   Journal for ImmunoTherapy of Cancer

Tumor microenvironment as a therapeutic target in cancer

(2020) Yi Xiao et al.   PHARMACOLOGY & THERAPEUTICS

Pituitary Adenoma in Pediatric and Adolescent Populations

(2019) Jie Chen et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors

(2019) Mizuto Sato et al.   Journal of Clinical Medicine

Management of Nonfunctioning Recurrent Pituitary Adenomas

(2019) Christopher J. Farrell et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours

(2019) Pedro Marques et al.   Acta Neuropathologica Communications

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

(2018) Curtis H. Kugel et al.   CLINICAL CANCER RESEARCH

Aggressive and malignant pituitary tumours: state-of-the-art

(2018) Dorota Dworakowska et al.   ENDOCRINE-RELATED CANCER

The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy

(2018) Peng-fei Wang et al.   JOURNAL OF NEURO-ONCOLOGY

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy

(2018) Jinfang Zhang et al.   TRENDS IN BIOCHEMICAL SCIENCES

Diagnosis and Treatment of Pituitary Adenomas

(2017) Mark E. Molitch   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Microscopic endonasal transsphenoidal pituitary adenomectomy in the pediatric population

(2016) Phiroz E. Tarapore et al.   Journal of Neurosurgery-Pediatrics

Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas

(2015) Jian-Qiang Lu et al.   ENDOCRINE PATHOLOGY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Transnasal Transsphenoidal Surgical Method in Pediatric Pituitary Adenomas

(2015) M. �zg�r Taskapilioglu et al.   PEDIATRIC NEUROSURGERY

Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma

(2014) S Han et al.   BRITISH JOURNAL OF CANCER

Aging disturbs the balance between effector and regulatory CD4+ T cells

(2014) Kornelis S.M. van der Geest et al.   EXPERIMENTAL GERONTOLOGY

Invasive adenoma and pituitary carcinoma: a SEER database analysis

(2014) Tara M. Hansen et al.   NEUROSURGICAL REVIEW

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer

(2009) Franck Pagès et al.   JOURNAL OF CLINICAL ONCOLOGY